VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Ferris on Potential of Nivolumab in Head and Neck Cancer

Robert Ferris, MD, PhD
Published: Friday, Feb 19, 2016



Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and coleader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses nivolumab's potential as a treatment for patients with head and neck cancer, as reported in the CheckMate-141 study.

Anti–PD-1 has been an exciting target and therapeutic approach since early phase data have been presented the past couple of years, Ferris explains. In the phase III randomized CheckMate-141 trial, patients with head and neck cancer who were cisplatin-refractory were randomized to receive nivolumab or standard chemotherapy.

CheckMate-141 was stopped early due to a positive endpoint of overall survival in the nivolumab arm. This data also adds a fourth modality—immunotherapy—to the treatment landscape of head and neck cancer, Ferris says.

<<< View more from the 2016 Multidisciplinary Head and Neck Cancer Symposium



Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and coleader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses nivolumab's potential as a treatment for patients with head and neck cancer, as reported in the CheckMate-141 study.

Anti–PD-1 has been an exciting target and therapeutic approach since early phase data have been presented the past couple of years, Ferris explains. In the phase III randomized CheckMate-141 trial, patients with head and neck cancer who were cisplatin-refractory were randomized to receive nivolumab or standard chemotherapy.

CheckMate-141 was stopped early due to a positive endpoint of overall survival in the nivolumab arm. This data also adds a fourth modality—immunotherapy—to the treatment landscape of head and neck cancer, Ferris says.

<<< View more from the 2016 Multidisciplinary Head and Neck Cancer Symposium




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x